GenOway: Revenue Up 10% in H1 2026, Focus on Asia and Catalogue
GenOway reported total revenues of €10.9M in the first half of 2026, a 10% increase from the first half of 2025. Behind this moderate rise, a strategic reallocation is taking shape: the group is now focusing on its catalogue model business and international expansion in Asia to accelerate growth, anticipating an increase of over 20% in the second half.
10% Growth in the First Half, Driven by Asia
GenOway and its Chinese joint venture, genOway Shanghai, reached total revenues of €10.9M in the first half of 2026, up from €9.9M a year earlier. This 10% increase masks an uneven dynamic across regions. The catalogue models business reached €7.7M, up 7% from the second half of 2025, confirming a solid growth trend despite a challenging American biotech environment. Conversely, the custom models business saw a significant decline, totaling €0.7M. The group is embracing this shift: reallocating its commercial resources towards the catalogue, deemed more strategic and less exposed to Asian competition. The custom segment, suffering from severe competition from Asian players, does not offer the stability required to ensure sustainable margins according to the management.
GenOway Shanghai: A Major Growth Driver with €2.4M
GenOway Shanghai, a joint venture established in December 2023, generated €2.4M in revenue in the first half of 2026. This entity now represents more than a fifth of the group's total revenues and embodies the strategic bet on Asia. The group confirms its target of achieving several tens of millions of euros in revenue in the medium term for this Chinese subsidiary. Concurrently, genOway has opened new commercial structures in other geographic areas, showing commercial traction described as encouraging. In the medium term, international activities outside the United States and main European countries are expected to generate about €20M in revenue, nearly two-thirds of the revenue achieved in the US and main European markets.
Guidance for Growth Exceeding 20% in the Second Half
GenOway anticipates a total revenue growth exceeding 20% in the second half of 2026, marking a significant acceleration compared to the first half of the year. Specifically for the catalogue activity, the company targets growth exceeding 15% in the second half. This outlook is supported by a strong order book and the acceleration of genOway Shanghai. The group is actively working on concluding strategic distribution partnerships, particularly in the United States, to leverage partner sales teams and multiply its sales. GenOway considers the realization of this goal in the coming months realistic. Strategically, the group maintains its target revenue goal of €50M by 2028, embedding this expected acceleration into a longer-term plan named Route50+data. The rollout of the data strategy, based on the acquisition of the OMICS-AI platform from Bioaster announced in December 2025, is proceeding according to plan and will be subject to specific communications later.
